Genomic testing in high-risk prostate cancer remains underutilized nationally, driven by fragmented ordering and interpretive ...

For robotic radical prostatectomy, the Retzius-sparing approach permits early urinary continence recovery but prostate cancer outcomes might be compromised.

The New Era of Tumor-Agnostic Cancer Therapy / ALK, Allen Chen, BCR ABL, Bence Jones proteins, biomarkers, BRAF, CA 19-9, ...

A single patient with one of the rarest and most aggressive salivary gland malignancies has provided oncologists with an ...

IMFINZI with IMJUDO and Platinum-Based Chemotherapy Immune-mediated pneumonitis occurred in 3.5% (21/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation ...

Cancer diagnoses are projected to hit 2.1 million in 2026, even as decades of progress have driven a 35% decline in the ...

Must-Read Posts In GU Oncology This Week / cancer, cancer care, Cancer research, cancer treatment, clinical trials, GU ...

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic ...

The world’s largest gathering of radiation oncology professionals opens here this week, and the research lineup suggests the ...

US FDA approves Welireg plus Lenvima for certain previously treated adult patients with advanced RCC with a clear cell component: Rahway, New Jersey Monday, September 28, 2026, 14 ...

Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...